Management of Antipsychotic-Induced Side Effects
Primary Clinical Rationale
- The Endocrine Society recognizes that aripiprazole augmentation has demonstrated beneficial effects for reducing hyperprolactinemia and sexual dysfunction caused by risperidone 1
- Aripiprazole's partial D2 agonist properties can normalize prolactin levels elevated by risperidone's D2 antagonism, allowing continuation of risperidone while addressing its prolactin-related adverse effects 1
- The National Institute of Mental Health supports the metabolic benefit profile of aripiprazole, which typically improves rather than worsens metabolic parameters, making it useful when risperidone causes weight gain or metabolic syndrome 1
Guideline Perspective on This Combination
- NICE advises against regular combined antipsychotic medication except for short periods when changing medications, and the American Psychiatric Association endorses monotherapy 1
- The World Federation of Societies of Biological Psychiatry only recommends considering antipsychotic polypharmacy in treatment-resistant schizophrenia 1
Alternative Explanations
- For treatment-resistant schizophrenia where monotherapy has failed, adding a second antipsychotic might be considered, though clozapine would be the preferred next step, according to the guideline society 1
- Only one-third of patients with SSRI-resistant OCD show clinically meaningful response to antipsychotic augmentation, suggesting limited efficacy of polypharmacy approaches, as reported by the guideline society 2
Critical Monitoring Requirements
- Extrapyramidal symptoms must be monitored closely due to additive dopaminergic effects, and metabolic parameters require ongoing assessment, as recommended by the guideline society 1
- Prolactin levels should be checked to confirm the intended benefit is achieved, according to the guideline society 1